| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7579321 | ACERUS PHARMS | Pharmaceutical compositions including low dosages of desmopressin |
May, 2023
(11 months ago) | |
| US7405203 | ACERUS PHARMS | Pharmaceutical compositions including low dosages of desmopressin |
May, 2023
(11 months ago) | |
| US7799761 | ACERUS PHARMS | Pharmaceutical compositions including low dosages of desmopressin |
Sep, 2024
(5 months from now) | |
| US9539302 | ACERUS PHARMS | Safe desmopressin administration |
Jun, 2030
(6 years from now) | |
| US11419914 | ACERUS PHARMS | Safe desmopressin administration |
Jun, 2030
(6 years from now) | |
Noctiva is owned by Acerus Pharms.
Noctiva contains Desmopressin Acetate.
Noctiva has a total of 5 drug patents out of which 2 drug patents have expired.
Expired drug patents of Noctiva are:
- US7579321
- US7405203
Noctiva was authorised for market use on 03 March, 2017.
Noctiva is available in spray, metered;nasal dosage forms.
Noctiva can be used as a method of treating nocturia due to nocturnal polyuria in adults, treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void by inducing an antidiuretic effect by intranasally administering a plume of droplets comprising a dose of about 0.05-5 mcg desmopressin.
The generics of Noctiva are possible to be released after 15 June, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 03, 2020 |
Drugs and Companies using DESMOPRESSIN ACETATE ingredient
Market Authorisation Date: 03 March, 2017
Treatment: A method of treating nocturia due to nocturnal polyuria in adults; Treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void by inducing an antidiuretic e...
Dosage: SPRAY, METERED;NASAL
NOCTIVA family patents
